Plasma Fatty Acid Ratios Affect Blood Gene Expression Profiles - A Cross-Sectional Study of the Norwegian Women and Cancer Post-Genome Cohort

Karina Standahl Olsen1*, Christopher Fenton2, Livar Frøyland3, Marit Waaseth4, Ruth H. Paulssen2, Eiliv Lund1

1 Department of Community Medicine, University of Tromsø, Tromsø, Norway, 2 Department of Clinical Medicine, University of Tromsø, Tromsø, Norway, 3 National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway, 4 Department of Pharmacy, University of Tromsø, Tromsø, Norway

Abstract

High blood concentrations of n-6 fatty acids (FAs) relative to n-3 FAs may lead to a “physiological switch” towards permanent low-grade inflammation, potentially influencing the onset of cardiovascular and inflammatory diseases, as well as cancer. To explore the potential effects of FA ratios prior to disease onset, we measured blood gene expression profiles and plasma FA ratios (linoleic acid/alpha-linolenic acid, LA/ALA; arachidonic acid/eicosapentaenoic acid, AA/EPA; and total n-6/n-3) in a cross-section of middle-aged Norwegian women (n = 227). After arranging samples from the highest to the lowest for all three FA ratios (LA/ALA, AA/EPA and total n-6/n-3), the highest and lowest deciles of samples were compared. Differences in gene expression profiles were assessed by single-gene and pathway-level analyses. The LA/ALA ratio had the largest impact on gene expression profiles, with 135 differentially expressed genes, followed by the total n-6/ n-3 ratio (125 genes) and the AA/EPA ratio (72 genes). All FA ratios were associated with genes related to immune processes, with a tendency for increased pro-inflammatory signaling in the highest FA ratio deciles. Lipid metabolism related to peroxisome proliferator-activated receptor γ (PPARγ) signaling was modified, with possible implications for foam cell formation and development of cardiovascular diseases. We identified higher expression levels of several autophagy marker genes, mainly in the lowest LA/ALA decile. This finding may point to the regulation of autophagy as a novel aspect of FA biology which warrants further study. Lastly, all FA ratios were associated with gene sets that included targets of specific microRNAs, and gene sets containing common promoter motifs that did not match any known transcription factors. We conclude that plasma FA ratios are associated with differences in blood gene expression profiles in this free-living population, and that affected genes and pathways may influence the onset and progression of disease.

Introduction

The type and amount of fatty acids (FAs) in a person’s diet determine the relative amounts of FAs in the tissues of the body, and may influence the pathogenesis of cardiovascular and inflammatory diseases, as well as cancer [1–5]. A multitude of mechanisms have been shown to influence disease pathogenesis, including lipid metabolism and inflammation. To study the complex molecular mechanisms involved in the association between nutritional factors and multifactorial diseases, high-throughput technologies like transcriptomics are increasingly being used.

The importance of dietary fat is mirrored in the complexity of FA metabolism. After ingestion, or following lipolysis in adipose tissue, FAs enter the blood stream either esterified in lipoproteins or non-esterified bound to albumin. FAs are transported into cells throughout the body, where they may be degraded by (per-) oxidation, stored as triglycerides, or incorporated into the phospholipids of cellular membranes. Membrane phospholipids can be modified into lipid mediators such as inositol triphosphate (IP$_3$), and FAs residing in the cellular membranes can be mobilized through the action of phospholipases and undergo modifications to yield a variety of immunomodulatory eicosanoids. Furthermore, FAs are potent regulators of gene expression via receptors like the peroxisome proliferator-activated receptors (PPARs) [4,5]. Collectively, PPARs and their binding partners, retinoid X receptors (RXR), regulate cellular and physiological processes including FA metabolism, cellular stress, and inflammation.

A key aspect of FA biology is the specificity inferred by the FA structure, as well as the fact that dietary sources differ in the FAs they contain. Two long-chain polyunsaturated FAs (PUFAs) are essential to humans and must be obtained from the diet: linoleic acid (LA, 18:2 n-6) and alpha-linolenic acid (ALA, 18:3 n-3), both of which are derived mainly from plant oils. LA is metabolized to arachidonic acid (AA, 20:4 n-6), whereas ALA is converted to eicosapentaenoic acid (EPA, 20:5 n-3) and docosahexaenoic acid (DHA, 22:6 n-3). This metabolism of PUFAs is extremely limited in humans [6]. In addition, mammals cannot convert n-6 FAs to n-
3 FAs [7], making the two classes metabolically distinct. n-6 and n-3 PUFAs compete for the same enzyme systems, so that the conversion of ALA to EPA and DHA is further reduced in individuals who adhere to a Western diet, due to the high intake of LA. Hence, EPA and DHA are mainly provided from dietary marine sources.

It has been suggested that n-6 FAs are pro-inflammatory, whereas n-3 FAs are much less so, and sometimes even anti-inflammatory. The ratio of n-6/n-3 FAs has been implicated in the pathogenesis of conditions like inflammatory and cardiovascular diseases, as well as cancers of the breast, prostate and colon [1,8,9]. A dietary n-6/n-3 ratio of 1 may be considered healthy, corresponding to a 50% n-3 FA content in tissues, but the typical Western diet provides a considerably higher n-6/n-3 ratio [10]. However, a relatively high n-6 intake and low n-6/n-3 ratio is observed in Norwegians, who consume high amounts of fish, fish products and fish oil supplements compared to other Western populations [11,12]. Effects of dietary intervention studies to reduce the n-6/n-3 ratio in healthy subjects include a reduced number of platelets and leukocytes [13], and beneficial modulation of metabolic and inflammatory markers [14,15]. The involvement of inflammatory mechanisms in the association between n-6/n-3 ratio and disease has led to the hypothesis that a high n-6/n-3 ratio may cause a "physiological switch" towards a permanent state of low-grade inflammation, which may be detrimental to several aspects of human health [1,16].

Despite the overarching hypothesis of a "physiological inflammatory switch", genome-wide transcriptomics studies exploring the potential effects of the n-6/n-3 ratio in the general population are scarce. However, some intervention studies have used FA supplementation to investigate the effects on gene expression levels. One targeted study of healthy adults showed reduced expression of selected signal transduction genes and pro-inflammatory cytokines after a 40% reduction of the n-6/n-3 ratio [17]. In addition, short and long-term effects of FA supplementation on genome-wide transcription in blood cells has been investigated [18]. Postprandial gene expression changes were found in peripheral blood mononuclear cells (PBMCs) after a DHA-rich meal, including up-regulation of stress genes and down-regulation of lipid metabolism [19]. After long-term supplementation (26 weeks) with EPA/DHA in an elderly population, PBMC gene expression levels related to inflammatory and atherogenic pathways were decreased [5].

Taken together, molecular and epidemiological studies indicate the importance of the n-6/n-3 ratio in relation to the prevention of inflammatory and cardiovascular diseases, as well as cancer. However, the use of the n-6/n-3 ratio to monitor and modify risk factors related to human disease is not without controversy [20]. One important objection stems from the fact that the total n-6/n-3 ratio, which is often used in epidemiological studies, does not distinguish between different types of PUFAs, e.g. LA/ALA or AA/EPA ratios. Furthermore, the extrapolation of the positive effects of FA ratios on disease, to their potential effects during disease onset, has not been extensively evaluated. With the aim of exploring the potential mechanisms of FA ratios in disease prevention, we used data from the Norwegian Women and Cancer (NOWAC) Post-genome Cohort [21] to perform a cross-sectional analysis of middle-aged Norwegian women. We grouped the study population according to three plasma FA ratios (LA/ALA, AA/EPA and total n-6/n-3), and identified differences in blood gene expression profiles by comparing the highest versus the lowest FA ratio deciles. To our knowledge, the present study is the first to explore the genome-wide transcriptomic effects of FA ratios in a representative cohort.

### Materials and Methods

#### Study Population and Materials

The NOWAC Study [22] and the NOWAC Post-genome Cohort [21] have been described in detail elsewhere. Briefly, the Post-genome Cohort consists of 50 000 women born between 1943 and 1957. Invited women were asked to visit their general physician to have blood collected using a kit which they received by mail, and to answer a two-page questionnaire on anthropometric and lifestyle parameters (including use of dietary supplements, medication, and menstrual status). Blood samples and questionnaires were returned by mail to the NOWAC study center. A total of 500 women were randomly selected for the present study, 444 of whom returned blood samples and questionnaires during 2005 (response rate 89%). All women included in our study population successfully returned a citrate-buffered blood sample, and a PAXgene blood RNA collection tube, which conserves the RNA profile of all circulating cells (Preanalytix, Qiagen, Hilden, Germany). Blood samples were required to reach the study center and be frozen no more than 3 days after blood collection. Furthermore, all included women were required to be postmenopausal according to self-report and plasma hormone levels (99 excluded) [23]. Medication was classified into the following categories: diabetes, non-steroidal anti-inflammatory drugs (NSAIDs), statins, cardiovascular medication (diuretics, adrenergic beta antagonists, calcium channel blockers, renin-angiotensin system inhibitors (including combinations with diuretics) and other anti-hypertensives), and immune system-related medication. Based on this classification, 30 women taking diabetes medication, statins, and immune system-related medication were excluded. In addition, two women using anti-thrombotics, and one using hydroxychloroquine were excluded from the study. Women who had smoked during the week before blood collection were defined as smokers, and those who had taken n-3 capsules/oils and/or cod liver oil the week before blood collection were defined as users of n-3 supplements.

#### Ethics Statement

The NOWAC Post-genome Cohort study was approved by the Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate. All participants gave written informed consent.

#### RNA Extraction and Gene Expression Profiling

Details of experimental procedures have been described elsewhere [24]. Total RNA was isolated using the PAXgene Blood RNA Isolation Kit (Preanalytix, Qiagen, Hilden, Germany), according to the manufacturer’s protocol. RNA quantity, quality and integrity were assessed using the NanoDrop ND1000 spectrophotometer (Thermo Scientific, Wilmington, Delaware, USA) and the Experion automated electrophoresis system (BioRad Laboratories, Hemel Hempstead, UK); 39 samples were excluded due to low RNA quality or quantity. No globin reduction method was used, in line with our previous finding that showed no major benefit from reduction of globin RNA for the microarray platform employed in the present study [25]. Gene expression levels were measured using the Human Genome Survey Microarray V2.0 (Applied Biosystems, ABI, Life Technologies, Carlsbad, California, USA). The microarray contains 32 878 probes for the interrogation of 29 098 transcripts. ABI Expression System software was used to extract signal intensities and signal/noise ratios, and for
flagging of spots. Experimental details and required data files were submitted to Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo), under accession number GSE13299.

**Microarray Data Preprocessing and Normalization**

The Bioconductor/R statistical package was used for microarray data preprocessing (script available upon request). Standard ABI exclusion criteria were applied, removing probes with a signal/noise ratio of less than 3, or those that were flagged as irregular by the scanner. There were 10 784 probes that met the selection criteria, and these were included in the gene expression matrix. Missing values were imputed using the k-nearest neighbor method [26]. Arrays that displayed an irregular intensity pattern in the built-in controls were removed (n = 3). The gene expression data set was normalized using a quantile and control-based normalization approach [27] (script available upon request). Probes with very low variability (<0.1), or very low average log2 signal (<9.5), were removed.

**FA Measurements**

The National Institute of Nutrition and Seafood Research analyzed 34 unique FAs in citrate-buffered plasma samples, using rapid gas chromatography [28]. Failed measurements caused eight samples to be excluded. FA ratios were calculated from the mass of each FA.

**Statistical Analysis**

The final number of included women was 227. For this explorative analysis, gene expression matrices were generated by arranging samples (columns) from highest to lowest values for the three FA ratios considered (LA/ALA, AA/EPA and total n-6/n-3). Within each matrix only the highest and lowest decile of samples were compared (decile n = 23). Potential confounders were evaluated by comparing the highest and lowest deciles using independent sample t-tests with two-tailed p-values, Mann–Whitney U tests, and Chi square tests (SPSS Statistics 19, IBM, Armonk, New York), with p < 0.01 as the significance threshold. There was a small, but statistically significant age difference among women in the highest versus the lowest AA/EPA and total n-6/n-3 deciles. Changes in lipid metabolism during menopausal transition have been well characterized, but as of yet, time since menopause has not been reported to influence lipid profiles [29]. Because all of our study women were postmenopausal, we chose not to adjust for age in the analyses of gene expression profiles. T-tests in R, and Benjamini-Hochberg corrected p-values were used to evaluate differential gene expression between the highest and the lowest LA/ALA, AA/EPA and total n-6/n-3 deciles. Functional annotations of single genes were explored using www.genecards.org and The Database for Annotation, Visualization and Integrated Discovery v. 6.7 [30]. Lists of differentially expressed genes (Table 3, t-tests, adjusted p ≤ 0.01, 315 genes), followed by the total n-6/n-3 ratio (125 genes), and the AA/EPA ratio (72 genes). We present the top 10 up- and down-regulated genes (Table 4–6), and complete gene lists are available (Supplement).

**Results**

Our study population (n = 227) was slightly overweight, and one-quarter of them were smokers (Table 1). A majority of the study women had taken n-3 supplements, in concordance with previous findings in the Norwegian population [12]. Nevertheless, the population mean of all FA ratios was dominated by n-6 FAs. The mean LA/ALA ratio was approximately 50, mean AA/EPA ratio was approximately 4, and mean total n-6/n-3 ratio was approximately 6. The highest and lowest FA ratio deciles included 23 women each, and their characteristics are presented in Table 2 and Supplementary Table S1. There were no significant differences in body mass index, smoking, fasting and medication use between comparison groups (p < 0.01). There were no significant differences in main characteristics between the highest and lowest LA/ALA deciles. When comparing the highest versus the lowest AA/EPA deciles, the lowest decile was slightly older and had a higher frequency of n-3 supplement use. The same pattern of age and supplement use was present in the comparison of the highest versus the lowest total n-6/n-3 deciles. In the study population as a whole, users of n-3 supplements were slightly older than non-users (2 years older, p < 0.01, data not shown), but the age difference was statistically significant. The frequent use of supplements may be related to the AA/EPA ratio of the lowest AA/EPA decile and the lowest total n-6/n-3 decile (AA/EPA ratio 1.3 and 1.5, respectively), which may be regarded as balanced (Table 2). There were no significant differences between any of the FA ratio deciles regarding technical variables (time elapsed between blood collection and freezing of the blood sample, date of RNA extraction, or microarray lot numbers, data not shown).

The LA/ALA ratio was associated with the highest number of differentially expressed genes (Table 3, t-tests, adjusted p ≤ 0.01, 315 genes), followed by the total n-6/n-3 ratio (125 genes), and the AA/EPA ratio (72 genes). We present the top 10 up- and down-regulated genes (Table 4–6), and complete gene lists are available (Supplement).

| Characteristic | Mean or frequency |
|---------------|-------------------|
| Age           | 55.6 ± 3.5        |
| BMI           | 25.5 ± 4.4        |
| Smoking       | 59 (26%)          |
| Fasting       | 13 (7%)           |
| Time since meal (h) | 2.7 ± 3.7 |
| n-3 supplements | 130 (59%)       |
| NSAIDs        | 20 (9%)           |
| Cardiovascular medication | 30 (13%)      |
| HRT           | 39 (17%)          |
| LA/ALA        | 51.9 ± 17.8       |
| AA/EPA        | 4.3 ± 2.8         |
| n-6/n-3       | 6.1 ± 2.0         |

*Format for age, BMI, time since meal, and FA ratios: mean (standard deviation). Format for smoking, fasting, supplements and medication; frequency (percent). Missing: BMI: 3, smoking: 1, fasting: 27, n-3 supplements: 5.

**Abbreviations:** AA: arachidonic acid, ALA: alpha-linolenic acid, BMI: body mass index, EPA: eicosapentaenoic acid, h: hours, HRT: hormone replacement therapy, LA: linoleic acid, n-3 supplements: any combination of n-3 capsules/oils, cod liver oil or both, NSAIDs: non-steroidal anti-inflammatory drugs.

doi:10.1371/journal.pone.0067270.T001
differentially expressed genes included the PPAR related to catabolic processes and fat metabolism, including (Table 5 and Supplemental Table S3). Very few inflammatory decile.

Jak/STAT pathway was positively enriched in the highest LA/ALA any known transcription factors. According to GSEA (Table 8), the overlap). A significant overlap with gene sets corresponding to repair of DNA and RNA (e.g. Reactome unwinding of DNA, 18% pathway), and one related to function, packaging, maintenance and dependent IL12 pathway, and Systemic Lupus Erythematosus

regulators were differentially expressed, including PPAR (Table 4 and Supplemental Table S2). Key FA metabolism (Table 6 and Supplemental Table S4). The list of differentially expressed genes overlapped with 50 regulators were differentially expressed, including PPARγ binding partners. Interestingly, genes related to autophagy were more highly expressed in the lowest LA/ALA decile, including KIAA0831 and OPTN. The list of differentially expressed genes overlapped with 50 gene sets in MSigDB belonging to two major categories (Table 7 and Supplemental Table S5): one category involving immune processes, with up to 20% overlap (e.g. the IL10 pathway, NO2-dependent IL12 pathway, and Systemic Lupus Erythematosus pathway), and one related to function, packaging, maintenance and repair of DNA and RNA (e.g. Reactome unwinding of DNA, 18% overlap). A significant overlap with gene sets corresponding to targets of two miRNAs was identified, as well as with three gene sets with common promoter motifs. However, neither motif matched any known transcription factors. According to GSEA (Table 8), the Jak/STAT pathway was positively enriched in the highest LA/ALA decile.

When comparing the highest versus the lowest AA/EPA deciles, differentially expressed genes included the PPARγ target ABCG1 (Table 5 and Supplemental Table S3). Very few inflammatory genes were associated with the AA/EPA ratio. The list of differentially expressed genes overlapped with 24 gene sets mainly related to catabolic processes and fat metabolism, including phospholipid transport (17% overlap), and targets of transcription factors like LXRA/NR1H3 and RXRB (Table 7 and Supplemental Table S6). Seven gene sets that included targets of specific miRNAs were significant, including MIR-103/107 and MIR-7. GSEA revealed significant negative enrichment for sulfur metabolism in the highest AA/EPA decile (Table 8).

Differentially expressed genes resulting from the comparison of the highest versus the lowest total n-6/n-3 deciles included ABCG1, OSBP2 and PLA2, all involved in FA and lipid metabolism (Table 6 and Supplemental Table S4). The list of differentially expressed genes overlapped up to 14% with gene sets related to endoplasmic reticulum and Golgi function, vesicle transport and protein folding (Table 7 and Supplemental Table S7). Apoptotic gene sets were identified, as well as two miRNA target sets: MIR-326 and MIR-296. In addition, differentially expressed genes overlapped with two gene sets sharing promoter motifs that did not match any known transcription factors. According to GSEA, no pathways were significantly enriched according to total n-6/n-3 ratio.

Discussion

In this explorative analysis, we investigated LA/ALA, AA/EPA and total n-6/n-3 ratios measured in plasma, and their potential

---

**Table 2. Characteristics of the highest and lowest fatty acid ratio deciles.**

| FA ratio               | Weighted | LA/ALA | AA/EPA | n6/n3 |
|-----------------------|----------|--------|--------|-------|
| **Differently expressed** |          |        |        |       |
|                       |          |        |        |       |
| Up-regulated          |          |        |        |       |
| Down-regulated        |          |        |        |       |

**Abbreviations:** AA: arachidonic acid, ALA: alpha-linolenic acid, EPA: eicosapentaenoic acid, FA: fatty acid, LA: linoleic acid.

doi:10.1371/journal.pone.0067270.t003
### Table 4. Top 10 up- and down-regulated genes associated with LA/ALA ratio (p\(\leq 0.01\))*.

| Gene symbol | Gene name                                      | ABI probe ID | Entrez gene ID | Mean difference |
|-------------|-----------------------------------------------|--------------|----------------|-----------------|
| HDC         | Histidine decarboxylase                       | 194873       | 3067           | 1.41            |
| CPA3        | Carboxypeptidase A3 (mast cell)               | 100989       | 1359           | 1.36            |
| TCHHL1      | Trichohyalin-like 1 (basatin, S100 calcium-binding protein A17) | 132590       | 126637         | 1.20            |
| MYBPHL      | Myosin binding protein H-like                 | 201601       | 343263         | 1.18            |
| FeER1B      | FC epsilon receptor 1-beta-chain (MS4A2)      | 182643       | 2206           | 1.00            |
| ANPEP       | Alanyl (membrane) aminopeptidase (CD13)       | 102558       | 290            | 0.64            |
| GLT1D1      | Glycosyltransferase 1 domain-containing protein 1 | 185381       | 144423         | 0.63            |
| ZNF558      | Zinc finger protein 558                       | 124882       | 148156         | 0.63            |
| SLC22A9     | Solute carrier family 22 (organic anion/cation transporter) 9 | 206544       | 114571         | 0.62            |
| FABP4       | Fatty acid binding protein 4, adipocyte       | 150137       | 2167           | 0.61            |
| IFIT1L      | Interferon-induced protein with tetrmericopeptide repeats 1B | 112888 | 439996         | -0.75           |
| MINPP1      | Multiple inositol polyphosphate phosphatase 1  | 188640       | 9562           | -0.70           |
| OR2W3       | Olfactory receptor 2W3                        | 702434       | 343171         | -0.70           |
| FM63B       | Family with sequence similarity 63, member B  | 161432       | 54629          | -0.69           |
| GFI1        | Growth factor independent 1 transcription repressor (ZN1F63) | 121984 | 2672           | -0.69           |
| MATR3       | Matrin 3                                      | 229698       | 9782           | -0.66           |
| SNCA        | Synuclein, alpha (non A4 comp. of amyloid precursor) | 170285      | 6622           | -0.63           |
| MYBL1       | V-myb myeloblastosis viral oncogene homolog (avian)-like 1 | 207803 | 4603           | -0.63           |
| NR2C2AP     | Nuclear receptor 2C2-associated protein       | 211955       | 126382         | -0.59           |
| KLRG1       | Killer cell lectin-like receptor subfamily G, member 1 | 188801 | 10219          | -0.58           |

*Complete lists of differentially expressed genes (p\(\leq 0.01\)) are given in Supplemental Table S2.

**Abbreviations:** ABI: Applied Biosystems, ALA: alpha-linolenic acid, LA: linoleic acid.

### Table 5. Top 10 up- and down-regulated genes associated with AA/EPA ratio (p\(\leq 0.01\))*.

| Gene symbol | Gene name                                      | ABI probe ID | Entrez gene ID | Mean difference |
|-------------|-----------------------------------------------|--------------|----------------|-----------------|
| ABCB9       | ATP-binding cassette, sub-family B (MDR/TAP), member 9 | 155893 | 23457         | 0.68            |
| ZNF354A     | Zinc finger protein eZNF (transcription factor 17) | 214609 | 6940          | 0.64            |
| ENTPD4      | Ectonucleoside triphosphate diphosphohydrolase 4 (LYSAL1) | 226738 | 9583          | 0.56            |
| ZCCHC2      | Zinc finger, CCHC domain-containing protein 2  | 154456       | 54877          | 0.51            |
| RNMTL1      | RNA methyltransferase-like protein 1           | 135382       | 55178          | 0.51            |
| GRIN2C      | Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | 194729 | 2905         | 0.47            |
| PODNL1      | Podocan-like 1                                | 146598       | 79883          | 0.47            |
| CCL24       | Chemokine (C-C motif) ligand 24               | 120849       | 6369          | 0.44            |
| RN157       | Ring finger protein 157                       | 212544       | 114804         | 0.40            |
| C20orf26    | Chromosome 20 open reading frame 26          | 190962       | 26074          | 0.35            |
| HLA-DQA1    | Major histocompatibility complex, class II, DQ alpha 1 | 170258 | 3117         | -1.04           |
| LMOD2       | Leiomodin 2 (cardiac)                         | 187222       | 442721         | -0.80           |
| APLP2       | Amyloid beta (A4) precursor-like protein 2    | 223157       | 334            | -0.74           |
| GPR97       | G protein-coupled receptor 97                 | 112591       | 222487         | -0.61           |
| FBXO17      | F-box protein 17                              | 163400       | 115290         | -0.46           |
| TMEM132B    | Transmembrane protein 132B                   | 167812       | 114795         | -0.44           |
| PTK2        | Protein-tyrosine kinase 2 (FAK)               | 128624       | 5747           | -0.44           |
| OSBP2       | Oxyysterol-binding protein 2                  | 148957       | 23762          | -0.43           |
| C4orf22     | Chromosome 4 open reading frame 22           | 164838       | 255119         | -0.39           |
| ABCG1       | ATP-binding cassette, sub-family G (WHITE), member 1 | 210662 | 9619       | -0.39           |

*Complete lists of differentially expressed genes (p\(\leq 0.01\)) are given in Supplemental Table S3.

**Abbreviations:** AA: arachidonic acid, ABI: Applied Biosystems, EPA: eicosapentaenoic acid.

doi:10.1371/journal.pone.0067270.t004
doi:10.1371/journal.pone.0067270.t005
effect on blood gene expression in a cross-section of middle-aged Norwegian women. Despite the high consumption of fish and n-3-rich fish oil supplements among Norwegians [11,12], the population mean of all FA ratios was dominated by n-6 PUFAs. However, the AA/EPA ratio in the lowest AA/EPA and total n-6/n-3 deciles may be regarded as “balanced”, and reflects the frequent use of EPA-rich n-3 supplements in these groups.

When comparing the highest versus the lowest FA ratio deciles, genes and pathways related to inflammation were differentially expressed in all three considered FA ratios. In addition, the identification of genes related to lipid metabolism and autophagy may point to the importance of these processes in elucidating the molecular mechanism related to the differing health effects of n-6 versus n-3 FAs. In general, FAs may influence gene expression profiles via several routes. These include direct mechanisms, such as binding to nuclear transcription factors, but also indirect mechanisms such as production of IP$_3$ and DAG. These second messengers lead to modulation of cellular functions and secretion of signaling molecules including eicosanoids. Eicosanoids and messengers lead to modulation of cellular functions and secretion of cytokines and related factors in the highest LA/ALA decile. This pathway is regarded as a principal signaling cascade for numerous cytokines, and its enrichment in the highest LA/ALA decile may be related to the higher expression of several cytokines, chemokines, and corresponding receptors and activators in the same group (including IL1R2, IL10RB, CCL7, TLR8). Also, several pathways related to cytokines were among the overlapping gene sets reported in MSigDB. In line with the present findings in a free-living population that consumes high amounts of fish and n-3 supplements, several studies have reported that long-term fish oil supplementation may reduce cytokine production [18], with a potential benefit for inflammatory disease pathogenesis.

A key pro-inflammatory component of innate and adaptive immunity, TLR8, was up-regulated in the highest LA/ALA decile. Studies have shown that dietary n-3 FAs inhibit TLRs, with positive consequences for inflammatory and immune responses [32,33]. Furthermore, the expression level of TLR8 correlated with poor outcome and increased inflammation in ischemic stroke [34]. TLR8 is highly expressed in peripheral blood leukocytes, and upon activation leads to NF-kB activation and secretion of cytokines. In conjunction with the higher expression levels of cytokines and related factors in the highest LA/ALA decile, TLR8 expression level may be indicative of higher inflammatory status in this group. In support of this hypothesis, the receptor for the pro-inflammatory platelet activating factor, PTAFR, was up-regulated in the highest LA/ALA decile. PTAFR is known to trigger inflammatory and thrombotic cascades, and is important for development of cardiovascular disease. In a dietary intervention study, Ambring et al. [13] found reduced numbers of platelets after reducing the n-6/n-3 ratio, which may be mirrored in our data as

### FA Ratios and Inflammatory Signaling

Molecular and epidemiological studies have demonstrated the immunoregulatory effects of dietary FAs. In the present study, the LA/ALA ratio was associated with the largest number of differentially expressed genes compared to the other ratios, both for all genes combined, and regarding genes involved in inflammatory processes. At the pathway level, GSEA revealed that the pleiotropic Jak/STAT pathway was enriched in the highest LA/ALA decile. This pathway is regarded as a principal signaling cascade for numerous cytokines, and its enrichment in the highest LA/ALA decile may be related to the higher level of expression of several cytokines, chemokines, and corresponding receptors and activators in the same group (including IL1R2, IL10RB, CCL7, TLR8). Also, several pathways related to cytokines were among the overlapping gene sets reported in MSigDB. In line with the present findings in a free-living population that consumes high amounts of fish and n-3 supplements, several studies have reported that long-term fish oil supplementation may reduce cytokine production [18], with a potential benefit for inflammatory disease pathogenesis.

### Table 6. Top 10 up- and down-regulated genes associated with total n-6/n-3 ratio (p≤0.01)$^a$

| Gene symbol | Gene name                                               | ABI probe ID | Entrez gene ID | Mean difference |
|-------------|---------------------------------------------------------|--------------|----------------|----------------|
| SERPINC1    | Serpin peptidase inhibitor, clade B (ovalbumin), member 9 (P19) | 113696       | 5272           | 0.57           |
| MSMO1       | Methylsterol monooxygenase 1 (SC4MOL)                   | 157577       | 6307           | 0.56           |
| SNAP23      | Synaptosomal-associated protein, 23 kD                  | 188605       | 8773           | 0.55           |
| CACNB1      | Calcium channel, voltage-dependent, beta 1 subunit      | 206077       | 782            | 0.51           |
| SLC30A5     | Solute carrier family 30 (zinc transporter), member 5   | 209725       | 64924          | 0.51           |
| IL1R2       | Immunoglobulin superfamily containing leucine-rich repeat | 103786       | 3671           | 0.48           |
| CCD5A       | Coiled-coil domain containing 7B                        | 171388       | 124093         | 0.48           |
| ACOT13      | Acyl-coenzyme A thioesterase 13 (THEM2)                 | 137024       | 55856          | 0.46           |
| C12orf43    | Chromosome 12 open reading frame 43                     | 230584       | 64897          | 0.46           |
| DHX34       | DEAH (Asp-Glu-Ala-His) box polypeptide 34               | 210135       | 9704           | 0.45           |
| PRAC        | Prostate cancer susceptibility candidate (C17orf92)      | 177570       | 84366          | 0.64           |
| HG5         | Hepatocyte growth factor-regulated tyrosine kinase substrate | 118384     | 9146           | 0.62           |
| USP5        | Ubiquitin specific protease 5 (isopeptidase T)          | 195536       | 8078           | 0.60           |
| PL2AG6      | Phosphopholase A2, group VI (cytosolic, calcium-independent) | 149260   | 8398           | 0.55           |
| MRPL55      | Mitochondrial ribosomal protein L55                     | 216047       | 128308         | 0.55           |
| SCARF1      | scavenger receptor class F member 1                     | 172281       | 8578           | 0.54           |
| OSBP2       | Oxysterol-binding protein 2                             | 148957       | 23762          | 0.50           |
| ASC2        | Activating signal co-integrator 1 complex subunit 2 (p100) | 186213       | 84164          | 0.50           |
| NELF        | Nasal embryonic luteinizing hormone-releasing hormone factor | 159936     | 26012          | 0.47           |
| ABCG1       | ATP-binding cassette, sub-family G (WHITE), member 1     | 210662       | 9619           | 0.47           |

$a$Complete lists of differentially expressed genes (p≤0.01) are given in Supplemental Table S4.

**Abbreviations:** ABI: Applied Biosystems.

doi:10.1371/journal.pone.0067270.t006
Table 7. Significant overlaps between differentially expressed genes and reported gene sets in MSigDb.

| FA ratio | Gene Set Name                        | K | k | k/K |
|----------|--------------------------------------|---|---|-----|
| LA/ALA   | KRTCTNINNMANAGC Unknown              | 60| 6 | 10% |
|          | Immune response                      | 232| 11| 5%  |
|          | Reactome Packaging of telomere ends  | 49 | 5 | 10% |
|          | Reactome Telomere maintenance        | 77 | 6 | 8%  |
|          | Immune system process                | 326| 12| 4%  |
|          | Kegg nitrogen metabolism             | 23 | 3 | 13% |
|          | RYAAWNNNTGAY Unknown                 | 53 | 4 | 8%  |
|          | Locomotory behavior                  | 91 | 5 | 5%  |
|          | Positive regulation of defence response | 10 | 2 | 20% |
|          | Response to external stimulus        | 306| 10| 3%  |
|          | Reactome RNA Pol I promoter opening  | 59 | 4 | 7%  |
|          | Reactome DNA strand elongation       | 31 | 3 | 10% |
|          | Hydrolase activity acting on ester bonds | 264| 9 | 3%  |
|          | Reactome Unwinding of DNA            | 11 | 2 | 18% |
|          | Cofactor transport                   | 11 | 2 | 18% |
|          | Reactome Signal attenuation          | 11 | 2 | 18% |
| AA/EPA   | Phospholipid transporter activity    | 12 | 2 | 17% |
|          | Lipid transporter activity           | 27 | 2 | 7%  |
|          | Nuclear body                        | 33 | 2 | 6%  |
|          | TCTAGAG, MIR-517                    | 37 | 2 | 5%  |
|          | Kegg ABC Transporters               | 44 | 2 | 5%  |
|          | Biocarta Mitochondria pathway       | 21 | 2 | 14% |
|          | Reactome Intrinsic pathway for apoptosis | 29 | 3 | 4%  |
|          | Apoptotic program                   | 60 | 2 | 10% |
|          | CCGAGAG,MIR-326                     | 135| 4 | 3%  |
|          | SCGGAAGY_VSELK1_02                  | 822| 6 | 2%  |
|          | Post Golgi vesicle mediated transport| 14 | 2 | 7%  |
|          | Intracellular transport              | 271| 5 | 2%  |

*The table is sorted by p-values with the lowest first, all p-values < 0.01. Number of genes submitted for comparison was 184 for LA/ALA, 36 for AA/EPA, and 65 for n-6/n-3. Gene sets significant at p < 0.05 are provided in Supplemental Tables S5–S7.

**Abbreviations:** AA: arachidonic acid, ALA: alpha-linolenic acid, EPA: eicosapentaenoic acid, FA: fatty acid, K: number of genes in gene set, k: number of genes in overlap, LA: linoleic acid.

doi:10.1371/journal.pone.0067270.t007

lower PTAFR expression levels in the lowest LA/ALA decile. The Fc receptor fragments FCGR1B also known as MS4A2, as well as GTP21, which is necessary for Fc heavy chain transcription, were up-regulated in the highest LA/ALA decile in our study. These fragments are part of the receptors for IgG and IgE, respectively, which are essential mediators of hypersensitive reactions. Conversely, the lower expression levels in the group with favorable LA/ALA ratios, may be viewed as an indication of lower immunological activation associated with lower ratio. The higher expression level of SRGN in the highest LA/ALA decile may also be indicative of hypersensitivity, as this protein is secreted from mast cell granules upon activation. Furthermore, the granzyme B inhibitor SERPINB9 was more highly expressed in the lowest total n-6/n-3 decile, fitting with a reduced immunological activity in the lowest FA ratio deciles.

A common denominator for the processes described above is the relation to hypersensitive reactions in people with conditions like asthma and allergies. Allergen binding to IgE and interaction with the Fc receptor ultimately leads to a release of eicosanoids, platelet activating factor, and cytokines like IL1. Collectively these mediators lead to activation and recruitment of inflammatory cells, which may be related to the increased expression of the chemotactic CCL7 (in the highest LA/ALA decile) and CCL24 (in the highest AA/EPA decile), and the cell migration-related PLAU (in the highest LA/ALA decile). Several of the identified pathway-level results support this hypothesis. In contrast, we found that a subunit of the antigen presenting MHC II complex, HLA-DQA1, was down-regulated in the highest AA/EPA decile. The molecular mechanisms described here in relation to immunoregulation by FAs, may be a part of the etiology of chronic inflammatory diseases, as suggested by others [35]. Recently, attention has been drawn to asthma and other atopic conditions as risk factors for chronic inflammatory diseases like diabetes and coronary heart disease [36]. The mechanisms of this association remain unclear, but immunological dysregulation is emerging as a potential link between atopy and chronic diseases [37]. Diet is a modifiable risk factor for several chronic diseases, and the gene expression patterns described here may constitute part of the complex and multifactorial links between diet, chronic inflammatory diseases, and atopic conditions.

Contrary to our prior hypothesis, few genes related to inflammatory signaling pathways were differentially expressed according to AA/EPA ratio. AA and EPA are precursors of a variety of inflammatory signaling molecules, and are fundamental to the implication of dietary PUFAs in inflammation [1]. However, in line with our results on gene expression in circulating blood cells, a recent review could make no firm conclusions about marine n-3 PUFAs and circulating inflammatory markers in healthy individuals, or in individuals with risk factors for cardiovascular disease [38].

The PPARγ Pathway may be Modulated by FA Ratios

Several genes related to lipid metabolism were differentially expressed according to FA ratios, and this was reflected in the pathway level analysis as well. Significant overlaps with reported gene sets from MSigDB included phospholipid transporter activity and Kegg ABC transporters (associated with the AA/EPA ratio), as well as post Golgi vesicle mediated transport and intracellular transport (associated with the total n-6/n-3 ratio). According to LA/ALA ratio, no pathway level processes were significant, but key FA metabolism regulators like RXRA, FABP4 (both binding partners for PPARγ), and ADIPOR1 were differentially expressed. These key regulators have been implicated in the pathogenesis of atherosclerosis, diabetes and metabolic diseases [39–41]. The PPARγ target ABCG1 was one of very few genes that were significantly associated with more than one FA ratio: it was expressed at lower levels in the highest AA/EPA and n-6/n-3 deciles. ABCG1 promotes cholesterol efflux from macrophages, and reduced expression in diabetes was related to increased foam cell formation [42]. The association of low ABCG1 levels with higher FA ratios in our dataset may provide hints to important
atherogenic consequences of ratios dominated by n-6 FAs. Taken together, one may speculate that the PPARγ pathway is modulated by differing FA ratios, and that possible health gains may be achieved via this pathway, by lowering FA ratios that are dominated by n-6 FAs.

**FA Ratios may Influence Autophagy**

Unexpectedly, several genes related to autophagy were expressed at higher levels in the lowest deciles of all FA ratios. Key genes included the positive regulator KIAA0831 (also known as Barcor/Angl4, up-regulated in lowest LA/ALA) and OPTN (also known as FIP2, up-regulated in the lowest LA/ALA and total n-6/n-3 deciles). Autophagy is emerging as a highly specific and diverse mechanism for lysosomal degradation of intracellular material, with numerous implications for cellular homeostasis, nutrient sensing, insulin regulation, and cholesterol metabolism [43]. Data is accumulating that demonstrates the close link between lipid metabolism and autophagy; lipid droplets may be degraded by autophagy, modulation of membrane lipids is essential for the process, and lipid modifying proteins have important regulatory roles [44]. Related processes include the inositol phosphate signaling system, endoplasmic reticulum stress, and oxysterol metabolism, all of which were reflected in our gene expression data. In line with our findings related to lipid metabolism and autophagy markers, a very recent cell line study showed induction of autophagy after n-3 FA supplementation, via the PPARγ pathway [45]. The potential influence of FA ratios on autophagy, and the impact of autophagy on health and disease, warrants further study.

**miRNAs and unknown Transcription Factor Motifs**

Differentially expressed genes derived from all FA ratios significantly overlapped with one or more gene sets that included targets of specific miRNAs. For example, miRNAs related to AA/EPA ratios included MIR-103/−107 and MIR-7, both shown to be involved in insulin and insulin-like growth factor signaling [46,47]. Total n-6/n-3 ratio was associated with MIR-326, which is involved in autoimmune diseases [48], and MIR-296, which is involved in regulation of angiogenesis [49] and lipopoapoptosis [50]. Transcriptional regulation by miRNAs may emerge as a mechanism for fine-tuning cellular and physiological responses to FAs. Furthermore, gene expression profiles according to LA/ALA and total n-6/n-3 ratios overlapped with gene sets containing common promoter motifs matching unknown transcription factors. One could speculate that transcription factors as yet unidentified may play a role in the complex transcriptional regulation in response to dietary lipids.

**Strengths and Limitations**

Because the Norwegian population consumes comparably high amounts of n-3 PUFAs, they constitute a “natural experiment” for exploring the potential effects of FA ratios. However, several issues arise in the interface between epidemiologic and molecular research. First, as this is an explorative, cross-sectional study, no conclusions can be made regarding causal mechanisms. Importantly, residual bias may be present in the data set, for example related to age, ongoing infections, or the variation in time since previous meal before blood sample collection.

There was a small, but statistically significant age difference between women in the highest versus lowest AA/EPA and total n-6/n-3 deciles. This was likely related to the finding that n-3 supplement users were slightly older than non-users in the study population. Age is known to influence metabolism of n-3 PUFAs, particularly during menopause. However, due to the use of supplements, the small age differences (3 years for AA/EPA ratio, and 4 years for total n-6/n-3 ratio), and our confirmed data on menopausal status, we chose not to adjust for age. This may have introduced bias in the data. Additional bias may have been introduced by confounders on which we had either limited or no information. For example, disease status could only be inferred from self-reported medication use, and no data on the distribution of blood cell subtypes were available. Because the PAXgene Blood RNA kit preserves RNA from all circulating cells, fluctuating levels of blood cell subtypes were related to an infection may influence gene expression profiles. The use of medication was not statistically different between comparison groups, but sub-clinical infections could still introduce differences in blood cell subtypes, and in turn, in the gene expression profiles.

In our study design, study women were not asked to fast before blood collection. Humans spend the majority of the day in a non-fasted, postprandial state, with a continuous fluctuation in the degree of lipemia [51]. Our biomarker of exposure, plasma total FAs, includes both the highly variable triglycerides (varies within hours and reflects FA content of the previous meal [52]), the cholesterol esters and phospholipids (varies within days) and the more stable non-esterified (free) FAs [53]. Thus, this biomarker may be said to reflect both intake and metabolism, and has been judged a valid biomarker, particularly for the exogenously derived long-chain PUFAs [53]. However, this biomarker renders us
unable to differentiate between short- versus long-term exposure to FAs. Studies have shown differing gene expression profiles after short (postprandial) and long-term exposure to n-3 EFAs. Postprandially, genes involved in lipid metabolism were regulated [19], and after long-term exposure inflammatory signaling was regulated [5]. In line with the properties of plasma FA ratios as a biomarker of exposure, we identified gene expression differences related to both lipid metabolism and inflammation.

Regarding the data analysis, GSEA can only identify gene sets that are being used as input, in this case pathways from KEGG, GO, and Panther. Recently characterized pathways like autophagy may be reported to involve somewhat non-overlapping sets of genes according to different databases, which poses difficulties for GSEA and overlap analysis. Lastly, we did not validate gene expression levels using other methods like quantitative real-time polymerase chain reaction or independent data sets, and our results must be interpreted accordingly.

Conclusions
We conclude that the plasma ratios of LA/ALA, AA/EPA and total n-6/n-3 may have differential impacts on blood gene expression in this cross-section of Norwegian middle-aged women. Genes and pathways associated with differing FA ratios may provide links to potential health consequences related to the balance of n-6 and n-3 PUFAs. Increased knowledge and awareness of the metabolic actions of dietary PUFAs is warranted, in order to form a sound basis on which to deliver evidence-based nutritional advice to the public.

Supporting Information
Figure S1 Venn diagram showing the overlap of differentially expressed genes by LA/ALA, AA/EPA and total n-6/n-3. Abbreviations: AA: arachidonic acid; ALA: alpha-linolenic acid; EPA: eicosapentaenoic acid; LA: linoleic acid. (TIFF)

Table S1 Additional characteristics of the study population (n = 227) and comparison groups (group n = 23). (XLSX)

References
1. Wall R, Ross RP, Fitzgerald GF, Stanton C (2010) Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr Rev 68: 280–289.
2. Simopoulos AP (2006) Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother 60: 502–507.
3. Jakobsen MU, O’Reilly EJ, Heimann BL, Perreira MA, Balter K, et al. (2009) Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies. Am J Clin Nutr 89: 1425–1432.
4. Dupuis E, Forest C (2002) Is there a single mechanism for fatty acid regulation of gene transcription? Biochemical Pharmacology 64: 893–901.
5. Bouwens M, van de Rest O, Delschaff N, Brounsaar MG, de Groot LC, et al. (2009) Fish-oil supplementation induces antiinflammatory gene expression profiles in human blood mononuclear cells. Am J Clin Nutr 90: 415–424.
6. Plourde M, Cunnane SC (2007) Extremely limited synthesis of long chain polyunsaturates in adults: implications for their dietary essentiality and use as supplements. Appl Physiol Nutr Metab 32: 619–634.
7. Svyacha JA, Kinney AJ, Brousse J (1997) Identification of an animal n=3 fatty acid desaturase by heterologous expression in Arabidopsis. Proceedings of the National Academy of Sciences 94: 1142–1147.
8. Goodstone SL, Zhong T, Holford TR, Ward BA, Carter D, et al. (2003) Dietary (n-3)/(n-6) fatty acid ratio: possible relationship to premenopausal breast cancer risk in U.S. women. The Journal of Nutrition 133: 1409–1414.
9. Berquin IM, Edwards BJ, Chen YQ (2000) Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Let 269: 363–377.
10. Hildebrand JR, Nieminen LR, Blasbalg TL, Riggs JA, Lands WE (2006) Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. The American Journal of Clinical Nutrition 83: S1403–149S.

Table S2 Differentially expressed genes according to LA/ALA ratio (t-tests, p < 0.01). (XLSX)

Table S3 Differentially expressed genes according to AA/EPA ratio (t-tests, p < 0.01). (XLSX)

Table S4 Differentially expressed genes according to total n-6/n-3 ratio (t-tests, p < 0.01). (XLSX)

Table S5 MsigDB gene set overlap based on LA/ALA ratio (p < 0.05). (XLSX)

Table S6 MsigDB gene set overlap based on AA/EPA ratio (p < 0.05). (XLSX)

Table S7 MsigDB gene set overlap based on total n-6/n-3 ratio (p < 0.05). (XLSX)

Acknowledgments
We gratefully acknowledge Ms. Bente Angdal and Ms. Merete Albrehtsen for organizing the collection of data and blood samples. Microarray experiments and analyses were performed at the Microarray Resource Centre Tromso (MRCT, microarray.fim.uio.no/GSCT). Blood lipids were analyzed by Dr. Yuge Figenschau, Department of Medical Biology, University of Tromso. We thank Professional Standards Editing and Ms. Trudy Perdrix-Thoma for excellent editing service.

Author Contributions
Conceived and designed the experiments: KSO EL. Performed the experiments: KSO LF. Analyzed the data: CF KSO. Contributed reagents/materials/analysis tools: RHP. Wrote the paper: KSO. Performed initial inclusion assessment and variable classification: MW. Critically revised the manuscript, and approved the final version: KSO CF LF MW RHP EL.

Table S2 Differentially expressed genes according to LA/ALA ratio (t-tests, p < 0.01). (XLSX)

Table S3 Differentially expressed genes according to AA/EPA ratio (t-tests, p < 0.01). (XLSX)

Table S4 Differentially expressed genes according to total n-6/n-3 ratio (t-tests, p < 0.01). (XLSX)

Table S5 MsigDB gene set overlap based on LA/ALA ratio (p < 0.05). (XLSX)

Table S6 MsigDB gene set overlap based on AA/EPA ratio (p < 0.05). (XLSX)

Table S7 MsigDB gene set overlap based on total n-6/n-3 ratio (p < 0.05). (XLSX)
19. Bouwens M, Georgette Bromhaar M, Jamus J, Muller M, Afman LA (2009) Postprandial dietary lipid-specific effects on human peripheral blood mononuclear cell gene expression profiles. Am J Clin Nutr: ajcn.2009.28586.

20. Griffin RA (2008) How relevant is the ratio of dietary n-6 to n-3 polyunsaturated fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study. Curr Opin Lipidol 19: 57–62.

21. Dumeaux V, Borresen-Dale AL, Frantzen JO, Kumble M, Kristensen V, et al. (2008) Gene expression analyses in breast cancer epidemiology: the Norwegian Women and Cancer cohort study. Breast Cancer Research 10: R15.

22. Land E, Dumeaux V, Braaten T, Hjartaker A, Engeset D, et al. (2008) Cohort profile: The Norwegian Women and Cancer Study - NOWAC - Kvinner og kreft. Int J Epidemiol 37: 36–41.

23. Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, et al. (2008) Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort - a cross-sectional analysis. BMC Womens Health 8: 1.

24. Dumeaux V, Olsen KS, Niel G, Paulsen RH, Borresen-Dale AL, et al. (2010) Deciphering normal blood gene expression variation – The NOWAC post-genome study. PLoS Genet 6: e1000873.

25. Dumeaux V, Land E, Borresen-Dale AL (2008) Comparison of globin RNA processing methods for genome-wide transcriptome analysis from whole blood. Biomarkers in Medicine 2: 1121–21.

26. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17: 520–525.

27. Bolstad BM, Irizarry RA, Astrand M, Speed TP (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 1519–1525.

28. Araujo P, Nguyen TT, Froyland L, Wang J, Kang JX (2008) Evaluation of a rapid method for the quantitative analysis of fatty acids in various matrices. J Chromatogr A 1212: 106–113.

29. de Aloysio D, Gambacciani M, Meschia M, Pansini F, Modena AB, et al. (1999) Rapid method for the quantitative analysis of fatty acids in various matrices. J Chromatogr A 1212: 106–113.

30. de Aloysio D, Gambacciani M, Meschia M, Pansini F, Modena AB, et al. (1999) The effect of menopause on blood lipid and lipoprotein levels. Atherosclerosis 147: 147–153.

31. Hwang da W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 4: 44–57.

32. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America 102: 15545–15550.

33. Chopkin RS, Kim W, Lupton JR, McMurray DN (2009) Dietary docosahexaenoic and eicosapentaenoic acid: emerging mediators of inflammation. Prostaglandins Leukot Essent Fatty Acids 81: 187–192.

34. Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, et al. (2003) Differential modulation of Toll-like receptors by fatty acids. J Cell Physiol 228: 1314–1322.

35. Wan JB, Huang LL, Rong R, Tang R, Wang J, et al. (2010) Endogenously decreasing tissue n-6/n-3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arteriosclerosis, thrombosis, and vascular biology 30: 2487–2494.

36. Cazzola M, Calzetta L, Bettoncelli G, Novelli L, Cricelli C, et al. (2011) Asthma and comorbid medical illness. European Respiratory Journal 38: 42–49.

37. Huang YJ (2012) Influence of micronutrients on nutrition and inflammation. Allergy Asthma Immunol Res 4: 122–131.

38. Myhrstad M, Retterstøl K, Telle-Hansen V, Ottesdal I, Halvorsen B, et al. (2011) Toll-like receptors 7 and 8 expression is associated with poor outcome in patients with colorectal cancer. Inflammation Research 60: 399–409.

39. Cabré A, Lázaro I, Girona J, Manzanoares JM, Marimón F, et al. (2008) Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. Journal of Lipid Research 49: 1746–1751.

40. Furnahushi M, Ishimura S, Ota H, Miura T (2011) Lipid Chaperones and Metabolic Inflammation. International Journal of Inflammation 2011.

41. Altucci L, Leibowitz MD, Ogilvie KM, de Leza AR, Gronemeyer H (2007) RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6: 793–810.

42. Maukín JP, Nagelín MH, Wojcik AJ, Srimivasan S, Skallen MD, et al. (2008) Reduced Expression of ATP-Binding Cassette Transporter G1 Increases Cholesterol Accumulation in Macrophages of Patients With Type 2 Diabetes Mellitus. Circulation 117: 2783–2792.

43. Singh R, Cuervo AM (2011) Autophagy in the cellular energetic balance. Cell Metab 13: 495–504.

44. Knuverhult H, Simoons LA (2012) Lipids in autophagy: Constituents, signaling molecules and cargo with relevance to disease. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1821: 1133–1145.

45. Rovito D, Giordano C, Vizza D, Plasmina P, Barone I, et al. (2013) Omega-3 PUFA ethanolamides DHEA and EPEA induce autophagy through PPAR-gamma activation in MCF-7 breast cancer cells. J Cell Physiol 228: 1314–1322.

46. Trajkovski M, Haasser J, Soutschek J, Bhat B, Akin A, et al. (2011) MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 474: 649–653.

47. Jiang L, Lu X, Chen Z, Jin Y, Heilbrunder CE, et al. (2010) MicroRNA-7 targets IGF1R (insulin-like growth factor 1 receptor) in tongue squamous cell carcinoma cells. Biochemical Journal 412: 199–205.

48. Sebastiani G, Grieco FA, Spagnuolo I, Galleri L, Cataldo D, et al. (2011) Increased expression of microRNA miR-296 in type 1 diabetic patients with ongoing islet autoimmunity. Diabetes/Metabolism Research and Reviews 27: 862–866.

49. Würdinger T, Taamouza BA, Saydam O, Skog J, Grau S, et al. (2008) miR-296 regulates growth factor receptor overexpression in Angiogenic Endothelial Cells. Cancer Cell 14: 392–392.

50. Cazzzone MC, Morl JL, Elmi NA, Brook SF, Manouka HC, et al. (2011) A role for miR-296 in the regulation of lipoprotein metabolism by targeting PUMA. Journal of Lipid Research 52: 1517–1525.

51. Hyson D, Rutledge JC, Berglund L (2003) Postprandial lipemia and cardiovascular disease. Current atherosclerosis reports 5: 437–444.

52. Burdge GC, Powell J, Calder PC (2006) Lack of effect of meal fatty acid composition on postprandial lipid, glucose and insulin responses in men and women aged 50–65 years consuming their habitual diets. Br J Nutr 96: 489–500.

53. Arab I (2003) Biomarkers of Fat and Fatty Acid Intake. J Nutr 133: 9258–932.